A comparative study of [68Ga]Ga-FAPI-04 PET/MR and [18F]FDG PET/CT in the diagnostic accuracy and resectability prediction of ovarian cancer

Xi, Yun; Sun, Lingling; Che, Xin; Huang, Xin‐Yun; Liu, Hua; Wang, Qun; Meng, Hongping; Miao, Yuxin; Qu, Qian; Hai, Wangxi; Li, Biao; Feng, Weiwei

doi:10.1007/s00259-023-06235-y

Cited by 7 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET/MRI yields a PCI closer to surgical PCI than does DWI, especially in patients with high tumor loads who do not receive chemotherapy [ 82 ]. Xi et al [ 83 ] found that due to the extremely low liver and gastrointestinal background, 68 Ga-FAPI-04 PET/CT was more accurate in scoring the upper and right abdomen than 18 FDG PET/CT, while the left abdomen was prone to overestimation because of the stronger extension of the greater omentum and mesentery. However, the positivity rate of lower abdominal lesions was comparable to or even worse than that of 18 FDG PET/CT (89.19% vs. 94.59%, respectively) [ 83 ].…”

Section: Promising Imaging Strategies For Diagnosing Pmmentioning

confidence: 99%

“…Xi et al [ 83 ] found that due to the extremely low liver and gastrointestinal background, 68 Ga-FAPI-04 PET/CT was more accurate in scoring the upper and right abdomen than 18 FDG PET/CT, while the left abdomen was prone to overestimation because of the stronger extension of the greater omentum and mesentery. However, the positivity rate of lower abdominal lesions was comparable to or even worse than that of 18 FDG PET/CT (89.19% vs. 94.59%, respectively) [ 83 ]. Further, in the small intestine, PET/MRI is more sensitive and less specific than DWI [ 82 ].…”

Section: Promising Imaging Strategies For Diagnosing Pmmentioning

confidence: 99%

See 1 more Smart Citation

Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques

Fu,

Zhang,

Guo

et al. 2024

Korean J Radiol

View full text Add to dashboard Cite

Early diagnosis, accurate assessment, and localization of peritoneal metastasis (PM) are essential for the selection of appropriate treatments and surgical guidance. However, available imaging modalities (computed tomography [CT], conventional magnetic resonance imaging [MRI], and 18fluorodeoxyglucose positron emission tomography [PET]/CT) have limitations. The advent of new imaging techniques and novel molecular imaging agents have revealed molecular processes in the tumor microenvironment as an application for the early diagnosis and assessment of PM as well as real-time guided surgical resection, which has changed clinical management. In contrast to clinical imaging, which is purely qualitative and subjective for interpreting macroscopic structures, radiomics and artificial intelligence (AI) capitalize on high-dimensional numerical data from images that may reflect tumor pathophysiology. A predictive model can be used to predict the occurrence, recurrence, and prognosis of PM, thereby avoiding unnecessary exploratory surgeries. This review summarizes the role and status of different imaging techniques, especially new imaging strategies such as spectral photon-counting CT, fibroblast activation protein inhibitor (FAPI) PET/CT, near-infrared fluorescence imaging, and PET/MRI, for early diagnosis, assessment of surgical indications, and recurrence monitoring in patients with PM. The clinical applications, limitations, and solutions for fluorescence imaging, radiomics, and AI are also discussed.

show abstract

Section: Promising Imaging Strategies For Diagnosing Pmmentioning

confidence: 99%

Section: Promising Imaging Strategies For Diagnosing Pmmentioning

confidence: 99%

Imaging Evaluation of Peritoneal Metastasis: Current and Promising Techniques

Fu,

Zhang,

Guo

et al. 2024

Korean J Radiol

View full text Add to dashboard Cite

show abstract

“…The primary radiotracer in gynecologic oncology PET/MRI (and PET/CT) is 18 Ffluorodeoxyglucose (FDG), which targets increased glucose metabolism in malignancy. Some research studies have highlighted the benefits of prostate-specific membrane antigen (PSMA)-targeted 18 F-DCFPyL and 68 Ga-FAPI-04 (fibroblast activating protein inhibitor) in diagnosing and assessing the treatment of ovarian cancer [48,49]. Additionally, 68 Ga-FAPI-04, 68 Ga-RGD (arginine-glycine-aspartic acid peptide) and 18 F-EF5 have shown promise in diagnosing and planning radiation treatment for cervical cancer [50][51][52].…”

Section: Oncologic Pet Tracers and Patient Preparationmentioning

confidence: 99%

Application of PET/MRI in Gynecologic Malignancies

Ebrahimi,

Lundström,

Batasin

et al. 2024

Cancers

View full text Add to dashboard Cite

The diagnosis, treatment, and management of gynecologic malignancies benefit from both positron emission tomography/computed tomography (PET/CT) and MRI. PET/CT provides important information on the local extent of disease as well as diffuse metastatic involvement. MRI offers soft tissue delineation and loco-regional disease involvement. The combination of these two technologies is key in diagnosis, treatment planning, and evaluating treatment response in gynecological malignancies. This review aims to assess the performance of PET/MRI in gynecologic cancer patients and outlines the technical challenges and clinical advantages of PET/MR systems when specifically applied to gynecologic malignancies.

show abstract